RELAY THERAPEUTICS INC (RLAY)
US75943R1023 - Common Stock
Overall RLAY gets a fundamental rating of 3 out of 10. We evaluated RLAY against 588 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for RLAY as it has an excellent financial health rating, but there are worries on the profitability. RLAY is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year RLAY has reported negative net income.
RLAY had a negative operating cash flow in the past year.
RLAY had negative earnings in each of the past 5 years.
RLAY had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
RLAY has a Return On Assets of -71.15%. This is in the lower half of the industry: RLAY underperforms 66.04% of its industry peers.
RLAY has a Return On Equity of -79.85%. This is comparable to the rest of the industry: RLAY outperforms 51.54% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -71.15% | ||
| ROE | -79.85% | ||
| ROIC | N/A |
ROA(3y)-34.34%
ROA(5y)-30.19%
ROE(3y)-38.86%
ROE(5y)-33.56%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
RLAY does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
RLAY does not have a ROIC to compare to the WACC, probably because it is not profitable.
RLAY has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, RLAY has more shares outstanding
There is no outstanding debt for RLAY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
RLAY has an Altman-Z score of 1.93. This is not the best score and indicates that RLAY is in the grey zone with still only limited risk for bankruptcy at the moment.
RLAY's Altman-Z score of 1.93 is fine compared to the rest of the industry. RLAY outperforms 70.31% of its industry peers.
RLAY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.93 |
ROIC/WACCN/A
WACC9.27%
2.3 Liquidity
A Current Ratio of 25.44 indicates that RLAY has no problem at all paying its short term obligations.
RLAY has a Current ratio of 25.44. This is amongst the best in the industry. RLAY outperforms 97.10% of its industry peers.
RLAY has a Quick Ratio of 25.44. This indicates that RLAY is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 25.44, RLAY belongs to the best of the industry, outperforming 97.10% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 25.44 | ||
| Quick Ratio | 25.44 |
3. Growth
3.1 Past
RLAY shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -7.69%.
Looking at the last year, RLAY shows a very strong growth in Revenue. The Revenue has grown by 3602.61%.
RLAY shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -32.39% yearly.
EPS 1Y (TTM)-7.69%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-19.64%
Revenue 1Y (TTM)3602.61%
Revenue growth 3Y-32.39%
Revenue growth 5YN/A
Revenue growth Q2Q10118.4%
3.2 Future
Based on estimates for the next years, RLAY will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.09% on average per year.
The Revenue is expected to grow by 56.75% on average over the next years. This is a very strong growth
EPS Next Y-6.24%
EPS Next 2Y-0.68%
EPS Next 3Y2.86%
EPS Next 5Y9.09%
Revenue Next Year-99.22%
Revenue Next 2Y-35.71%
Revenue Next 3Y-45.26%
Revenue Next 5Y56.75%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for RLAY. In the last year negative earnings were reported.
Also next year RLAY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.68%
EPS Next 3Y2.86%
5. Dividend
5.1 Amount
RLAY does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
RELAY THERAPEUTICS INC
NASDAQ:RLAY (5/2/2024, 3:16:25 PM)
After market: 7.21 +0.13 (+1.84%)7.08
+0.42 (+6.31%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap928.75M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -71.15% | ||
| ROE | -79.85% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.06
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 25.44 | ||
| Quick Ratio | 25.44 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-7.69%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-6.24%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)3602.61%
Revenue growth 3Y-32.39%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y